Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Astria Therapeutics, Inc.

< Previous 1 2 3 Next >
Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Names Andrea Matthews Chief Business Officer
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Investment Conferences
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Names Chris Morabito Chief Medical Officer
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.